Work

Abstract B135: First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-b135

Authors: Timothy A. Yap, Kyriakos Papadopoulos, Ivy Fearen, Christopher Carpenter, Liliana Delgado, Adekemi Taylor, Julia Domsch, David Olmos, Andre T. Brunetto, Daniel S. Tan, Shaun Decordova, Simon P. Heaton, Michelle D. Garrett, Amita Patnaik, Daniel Sullivan, Li Yan, Johann S. de Bono, Anthony W. Tolcher

Institutions: Royal Marsden NHS Foundation Trust, South Texas Accelerated Research Therapeutics, Merck & Co., Inc., Rahway, NJ, USA (United States), Institute of Cancer Research, Moffitt Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2100263195

Cites:

Cited by: 1

Related to: 10